iparomlimab (QL1604) / Qilu Pharma - LARVOL DELTA

Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC (clinicaltrials.gov) - P2 | N=33 | Not yet recruiting | Sponsor: Changhai Hospital

New P2 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-eclipse for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial (SGO 2026) - No abstract available

Clinical • Metastases • P2 data • Cervical Cancer • Oncology • Solid Tumor

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer (clinicaltrials.gov) - P2 | N=70 | Not yet recruiting | Sponsor: Jiangsu Cancer Institute & Hospital

New P2 trial • Colorectal Cancer • Oncology • Solid Tumor • MSI

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC (clinicaltrials.gov) - P2 | N=27 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

New P2 trial • Tumor mutational burden • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • EGFR

Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial. (PubMed, J Gynecol Oncol) - P2 | "A total of 43 patients diagnosed with International Federation of Gynecology and Obstetrics 2018 stage IB3, IIA2, IIB, or IIIC1r will receive iparomlimab and tuvonralimab (5 mg/kg, intravenously), nab-paclitaxel (60 mg/m², intravenously), and cisplatin (75-80 mg/m², intravenously) for the first cycle. Additionally, the exploratory endpoint will focus on identifying predictive biomarkers associated with tumor response. ClinicalTrials.gov Identifier: NCT07055399."

IO biomarker • Journal • P2 data • Cervical Cancer • Cervical Squamous Cell Carcinoma • Gynecology • Obstetrics • Oncology • Solid Tumor • Squamous Cell Carcinoma • CTLA4

First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy (clinicaltrials.gov) - P2 | N=64 | Not yet recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University

New P2 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer (clinicaltrials.gov) - P2 | N=33 | Recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Pancreatic Cancer • Solid Tumor

Iparomlimab and Tuvonralimab in Combination with Nab-Paclitaxel and Apatinib as Second-Line Therapy for Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma: A Single-Center, Single-Arm IIT Study (ChiCTR) - P2 | N=20 | Not yet recruiting | Sponsor: Shanghai East Hospital; Shanghai East Hospital

New P2 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • HER-2 • MSI

An Exploratory Clinical Study of Lenvatinib Combined with Iparomlimab and Tuvonralimab and TACE for the Conversion Therapy of Potentially Resectable Hepatocellular Carcinoma (ChiCTR) - P4 | N=44 | Recruiting | Sponsor: The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University

New P4 trial • Hepatocellular Cancer • Oncology • Solid Tumor

The efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) combined with Lenvatinib as neoadjuvant therapy in renal cancer with partial nephrectomy indications but high surgical risk：A single arm, Phase II clinical study (ChiCTR) - P2 | N=25 | Not yet recruiting | Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

New P2 trial • Clear Cell Carcinoma • Clear Cell Renal Cell Carcinoma • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=33 | Recruiting | Sponsor: Jiangsu Cancer Institute & Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Tumor mutational burden • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • PD-L1 • ROS1

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer (clinicaltrials.gov) - P2 | N=68 | Recruiting | Sponsor: Dai, Guanghai

New P2 trial • Esophageal Cancer • Gastric Cancer • Oncology • Solid Tumor

Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab-Tuvorilimab for Advanced Gallbladder Cancer (ChiCTR) - P2 | N=44 | Not yet recruiting | Sponsor: Xinhua Hospital Affiliated to Shanghai Jiaotong University of Medicine; Xinhua Hospital Affiliated to Shanghai Jiaotong University of Medicine

New P2 trial • Gallbladder Cancer • Oncology • Solid Tumor

A Phase II, Prospective, Single-Arm, Multicenter, Open-Label Study of Sacituzumab tirumotecan in Combination with Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Locally Advanced Cervical Cancer (ChiCTR) - P2 | N=25 | Not yet recruiting | Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

New P2 trial • Cervical Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • PD-L1 • TACSTD2

Study on the efficacy and safety of NALIRIFOX in combination with Iparomlimab and Tuvonralimab Injection and SBRT as neoadjuvant therapy for resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors (ChiCTR) - P4 | N=35 | Not yet recruiting | Sponsor: West China Hospital, Sichuan Universit; West China Hospital, Sichuan Universit

New P4 trial • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

Study on the efficacy and safety of QL1706 combined with Senaparib in neoadjuvant therapy for ovarian Cancer: A prospective, single-arm clinical study (ChiCTR) - P=N/A | N=20 | Not yet recruiting | Sponsor: The Fourth Hospital of Hebei Medical University; Fourth Hospital of Hebei Medical University

New trial • Oncology • Ovarian Cancer • Solid Tumor

Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer. (clinicaltrials.gov) - P1 | N=14 | Recruiting | Sponsor: JIANG LONGWEI

New P1 trial • Colorectal Cancer • Oncology • Solid Tumor

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer (clinicaltrials.gov) - P2 | N=106 | Not yet recruiting | Sponsor: Peking University Cancer Hospital & Institute

IO biomarker • New P2 trial • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Rectal Cancer • Solid Tumor • BRAF • KRAS • NRAS

Iparomlimab and Tuvonralimab combined with fruquintinib in the treatment of dMMR/MSI-H colorectal cancer that has failed previous immune checkpoint inhibitor therapy: a single-center, single-arm, IIT trial (ChiCTR) - P2 | N=17 | Not yet recruiting | Sponsor: Shanghai East Hospital; Shanghai East Hospital

New P2 trial • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial (clinicaltrials.gov) - P2 | N=41 | Recruiting | Sponsor: Sun Yat-sen University | Not yet recruiting ➔ Recruiting

Enrollment open • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • PD-L1

Maintenance Therapy Options After R0 Resection for Oligorecurrent Ovarian Cancer Following PARPi Maintenance: A Phase IIB, Randomized, Multicenter Study (ChiCTR) - P2 | N=72 | Not yet recruiting | Sponsor: Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center

New P2 trial • Platinum sensitive • Oncology • Ovarian Cancer • Solid Tumor

Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=28 | Not yet recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A single-arm, multicenter, phase II clinical study of Tuvonralimab/Iparomlimab and docetaxel in patients with advanced non-small-cell lung cancer who have progressed following immune checkpoint inhibitor (ChiCTR) - P2 | N=43 | Recruiting | Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University | Not yet recruiting ➔ Recruiting | Initiation date: Jun 2025 ➔ Dec 2025

Enrollment open • Trial initiation date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • ROS1

Neoadjuvant Iparomlimab and Tuvonralimab for Resectable MSI-H/dMMR Gastric or Gastroesophageal Junction Cancer (NIT-GC study): a single-arm, openlabel, phase 2 trial (ChiCTR) - P2 | N=48 | Not yet recruiting | Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

New P2 trial • Esophageal Cancer • Gastric Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI

A Single-Arm, Multicenter Clinical Study of QL1706 Combined with XELOX as Neoadjuvant and Adjuvant Therapy for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma (ChiCTR) - P2 | N=28 | Not yet recruiting | Sponsor: Qilu Hospital of Shandong University (Qingdao); Qilu Hospital of Shandong University (Qingdao)

New P2 trial • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2 • PD-L1